Which adult with community-acquired pneumonia (CAP) benefits from intravenous (IV) hydrocortisone (corticosteroid) addition to standard therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The patient most likely to benefit from the addition of intravenous (IV) hydrocortisone to standard antibiotic therapy and supportive care is the patient admitted to the intensive care unit (ICU) who requires oxygen support with a nonrebreathing mask, with an estimated PaO2:FiO2 of 100. This recommendation is based on the findings from the Community-Acquired Pneumonia: Evaluation of Corticosteroids (CAPE COD) study, which suggest that patients with severe CAP and significant hypoxemia are more likely to benefit from corticosteroid therapy 1. The patient's PaO2:FiO2 ratio of 100 indicates severe hypoxemia, which is consistent with the criteria for benefit from corticosteroids in the CAPE COD study.

The use of corticosteroids in patients with severe CAP has been studied extensively, with some studies suggesting a benefit in reducing mortality and improving clinical outcomes 1. The IDSA/ATS 2019 guideline gives a strong conditional recommendation against routine use of adjunctive steroids in patients treated for CAP, but suggests that corticosteroids may be beneficial in patients with severe CAP, particularly those with septic shock refractory to fluid resuscitation and vasopressor use 1.

The recommended regimen for IV hydrocortisone would be 200 mg daily for 7 days, in addition to appropriate antibiotics and supportive care 1. This regimen is consistent with the guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients, which suggest the use of corticosteroids for 5-7 days at a daily dose < 400 mg IV hydrocortisone or equivalent in hospitalized patients with CAP 1.

Key points to consider when evaluating the potential benefit of corticosteroids in patients with CAP include:

  • Severity of hypoxemia, as indicated by the PaO2:FiO2 ratio
  • Presence of septic shock refractory to fluid resuscitation and vasopressor use
  • Elevated CRP levels (> 150 mg/L)
  • Need for mechanical ventilation or oxygen support
  • Potential risks and benefits of corticosteroid therapy, including the risk of increased mortality in patients with viral CAP 1.

From the Research

Patient Selection for IV Hydrocortisone Therapy

The decision to add intravenous (IV) hydrocortisone to standard antibiotic therapy and supportive care for adults with community-acquired pneumonia (CAP) should be based on the severity of the disease and the patient's response to initial treatment.

  • Patients with severe hypoxemia, defined as a PaO2:FiO2 ratio of less than 100 mmHg, may benefit from the addition of IV hydrocortisone to their treatment regimen 2.
  • The use of IV hydrocortisone in patients with CAP has been studied in various clinical trials, including the CAPE COD study, which aimed to evaluate the effectiveness of corticosteroids in patients with CAP.
  • Patients who require oxygen support with a nonrebreathing mask and have an estimated PaO2:FiO2 of 100 are more likely to benefit from IV hydrocortisone therapy compared to those with higher PaO2:FiO2 ratios 3, 4.

Comparison of Patient Scenarios

The following patient scenarios can be compared to determine which patient is most likely to benefit from IV hydrocortisone therapy:

  • A patient admitted to a medical floor with a Pulmonary Severity Index (PSI) score of 120 may not require IV hydrocortisone therapy, as their condition is not severe enough to warrant corticosteroid treatment.
  • A patient admitted to the intensive care unit (ICU) who requires mechanical ventilation with a positive end-expiratory pressure (PEEP) of 4 cm of water may benefit from IV hydrocortisone therapy, but their PaO2:FiO2 ratio is not provided.
  • A patient admitted to the ICU who requires oxygen support with high-flow nasal cannula and has an estimated PaO2:FiO2 of 400 is less likely to benefit from IV hydrocortisone therapy, as their PaO2:FiO2 ratio is relatively high.
  • A patient admitted to the ICU who requires oxygen support with a nonrebreathing mask and has an estimated PaO2:FiO2 of 100 is the most likely to benefit from IV hydrocortisone therapy, as their condition is severe and they have a low PaO2:FiO2 ratio 5, 6.

Related Questions

Why would one require 20 liters per minute (lpm) of oxygen at a fraction of inspired oxygen (FiO2) of 21%?
What are the initial FiO2 (fraction of inspired oxygen) and flow rate limits for Acute Care Unit (AAU) patients requiring High Flow Nasal Cannula (HFNC) support?
How to manage a patient with respiratory acidosis and hypoxemia?
What are the initial steps in managing acute breathlessness?
What is the treatment approach for a patient with severe hypoxemia and bradycardia, with an SpO2 of 60% on 10 liters of oxygen (O2) and a pulse rate of 45 beats per minute (bpm)?
What is valazodone (vlazodone), also known as Viibryd (vortioxetine)?
Why do the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) recommend concurrent use of Glycated Hemoglobin (HbA1c), Continuous Glucose Monitoring (CGM), and Self-Monitoring of Blood Glucose (SMBG) for monitoring glycemic control in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2D)?
What is the most appropriate initial antibiotic therapy for a 42-year-old female with community-acquired pneumonia (CAP), presenting with cough, fever, malaise, leukocytosis with bandemia, bilateral lower lobe infiltrates, and mild hypotension, who requires mechanical ventilation?
What is the treatment for cervical lymphadenopathy (enlarged cervical lymph nodes)?
How long should a heparin (unfractionated heparin) infusion be held preoperatively?
What are the severe side effects of long-term chronic opioid (narcotic analgesic) use?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.